Rallybio Sells Interest in Rare Disease Program to Recursion Pharmaceuticals for Up to $25 Million’
NEW HAVEN, Conn. Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company focused on the development of transformative therapies for patients with rare and devastating diseases, announced today that it has executed a definitive agreement to sell its interest in the REV102 program to joint venture partner Recursion Pharmaceuticals. The transaction, valued up to $25 million, centers on REV102, an ENPP1 inhibitor currently in preclinical development for the treatment of hypophosphatasia (HPP), a rare metabolic disorder.
The strategic divestiture aligns with Rallybio’s commitment to allocating resources towards advancing clinical-stage assets and supporting its robust pipeline of therapeutic solutions for underserved medical communities. By transitioning interest to Recursion Pharmaceuticals, a pioneer in the marriage of biology and digital technology, there is optimism that the program will benefit from accelerated development under Recursion’s innovative approach to drug discovery and development.
This move comes as Rallybio Corporation experiences noteworthy market performance. During the current month, its stock shares have delivered a 4.53% increase, outperforming broader market indices. Notably, Rallybio has also outstripped the performance of CSIMarkets index tracking its sector competitors and alternatives over the past week.
The agreement with Recursion Pharmaceuticals not only provides Rallybio with financial gains of up to $25 million that can be reinvested into its core priorities but also demonstrates the company’s strategic agility in partnering and prioritizing assets. With the backing of Recursion’s platform, the future development of the REV102 program could offer new hope to patients suffering from hypophosphatasia.
Rallybio’s leadership expressed confidence in Recursion’s capabilities, acknowledging that the combination of Rallybio’s deep biological insights with Recursion’s technology-driven development potentially unlocks significant value for both companies and patients afflicted by HPP.
As biotechnological advancements continue to evolve, collaborations such as this one highlight the importance of strategic partnerships tailored to enhance therapeutic development pathways and expedite solutions to market.
Comments